EZH2 and nonpapillary renal cell carcinoma: We noticed that in the TCGA cohort, tumors of the high EZH2 expression group were positively associated with stage IV in ccRCC (stage I, 40.78%; stage IV; 22.35%), pRCC (stage I, 63.89%; stage IV; 1.39%), and chRCC (stage I, 27.27%; stage IV; 6.06%) (Fig. 5C).